Floatz logo

42 assets in Myelodysplastic/Myeloproliferative Neoplasm

Therapeutic assets addressing Myelodysplastic/Myeloproliferative Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Etoposide
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP3BBB (77)
Busulfanum
Myelodysplastic/Myeloproliferative Neoplasm
Jacqueline Garcia, MDP2/3BBB (76)
Cyclosporin A
Myelodysplastic/Myeloproliferative Neoplasm
Memorial Sloan Kettering Cancer CenterP3BBB (76)
Cytarabine
Myelodysplastic/Myeloproliferative Neoplasm
Fred Hutchinson Cancer CenterP3BBB (76)
Melphalan
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2/3BBB (76)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2/3BBB (75)
Fludarabine
Myelodysplastic/Myeloproliferative Neoplasm
Fred Hutchinson Cancer CenterP3BBB (75)
Tacrolimus
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2BBB (73)
Cyclophosphamide
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP3BBB (72)
Thiotepa
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2/3BBB (72)
Carboplatin
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer InstituteP2/3BB (70)
Methotrexate
Myelodysplastic/Myeloproliferative Neoplasm
Alliance for Clinical Trials in OncologyP3BB (70)
Sirolimus
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer InstituteP2BB (69)
Decitabine
Myelodysplastic/Myeloproliferative Neoplasm
University of WashingtonP2BB (68)
Idarubicin
Myelodysplastic/Myeloproliferative Neoplasm
Fred Hutchinson Cancer CenterP3BB (66)
Ruxolitinib
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer InstituteP2BB (65)
Azacitidine
Myelodysplastic/Myeloproliferative Neoplasm
Karolinska University HospitalP2B (63)
Rituximab
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP2B (63)
Clofarabine
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2B (59)
Nogitecan
Myelodysplastic/Myeloproliferative Neoplasm
National Cancer Institute (NCI)P2B (57)
Venetoclax
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP1/2B (57)
Adriamycin
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP1CCC (55)
Fedratinib
Myelodysplastic/Myeloproliferative Neoplasm
University of WashingtonP2CCC (53)
NK-92
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2CCC (53)
Tranexamic Acid
Myelodysplastic/Myeloproliferative Neoplasm
University of ManitobaP2CCC (53)
Veliparib
Myelodysplastic/Myeloproliferative Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Edetate Calcium Disodium
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP1/2CCC (52)
Gilteritinib
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP1/2CCC (48)
Pevonedistat
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP1/2CCC (48)
Posaconazole
Myelodysplastic/Myeloproliferative Neoplasm
BeiGeneP1/2CC (47)
prt2527
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP1CC (47)
Sonrotoclax
Myelodysplastic/Myeloproliferative Neoplasm
BeiGeneP1/2CC (47)
Zanubrutinib
Myelodysplastic/Myeloproliferative Neoplasm
Prelude TherapeuticsP1CC (47)
Pacritinib
Myelodysplastic/Myeloproliferative Neoplasm
University of WashingtonP2CC (46)
cd33 fpbmc
Myelodysplastic/Myeloproliferative Neoplasm
University of VirginiaP1CC (43)
Cedazuridine
Myelodysplastic/Myeloproliferative Neoplasm
Jacqueline Garcia, MDP1CC (43)
Imgn632
Myelodysplastic/Myeloproliferative Neoplasm
Fred Hutchinson Cancer CenterP1CC (43)
lp-118
Myelodysplastic/Myeloproliferative Neoplasm
Newave Pharmaceutical IncP1CC (43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Myelodysplastic/Myeloproliferative Neoplasm
City of Hope Medical CenterP1CC (43)
Succimer
Myelodysplastic/Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP1CC (43)
Camidanlumab Tesirine
Myelodysplastic/Myeloproliferative Neoplasm
Gwynn Long, M.D.P2C (39)
Equine Atg
Myelodysplastic/Myeloproliferative Neoplasm
DKMS gemeinnützige GmbHP3NR ()